Table 2. Epidemiologic and clinical characteristics of index recipients associated with SARS-CoV-2 transmission in recipients of solid-organ transplants, United States, March–May 2020*.

Index recipient	Donor	Organ	Symptoms	No. days from transplant to symptom onset	Exposure to persons with COVID-19	No. days in hospital†	No. days in ICU‡	No. days intubated‡	COVID-19 treatment	Immunosuppressive medications, induction	Immunosuppressive medications, maintenance	Patient status
A	A	Bilateral lungs	Fever, respiratory failure, diaphoresis, atrial fibrillation, shock, acute kidney failure	6	Confirmed COVID-19 among HCW contacts, potential nosocomial transmission	109	35	41	Hydroxychloroquine, azithromycin	Basiliximab, methylprednisolone	Mycophenolate, tacrolimus, prednisone	Alive
B	B	Single lung	Fever, nasal congestion	14	Confirmed COVID-19 among HCW contacts	31	None	None	Hydroxychloroquine	Basiliximab, methylprednisolone	Mycophenolate, tacrolimus, prednisone	Alive
C	C	Liver	Altered mental status, fever, respiratory failure	9	Confirmed COVID-19 among household contacts	79	66	64	Convalescent plasma	Basiliximab	Everolimus, prednisone	Dead
D	D	Liver	Cough	7	Suspected nosocomial transmission at transplant center	49	19	19	Hydroxychloroquine, azithromycin	Methylprednisolone	Tacrolimus, mycophenolate mofetil, prednisone	Dead
E	E	Bilateral lungs	None	Asymptomatic	Confirmed COVID-19 among HCW contacts	17	4	2	Chloroquine	Basiliximab, methylprednisolone, mycophenolate mofetil	Tacrolimus, mycophenolate mofetil, prednisone	Alive
F	F	Single lung	Fever, dyspnea, wheezing	7	Suspected nosocomial transmission at transplant center	14	14	9	Remdesivir, azithromycin, intravenous immunoglobulin	Basiliximab	Tacrolimus, mycophenolate mofetil, prednisone	Dead
G	G	Heart and single kidney	Tachycardia, respiratory failure	81	Confirmed COVID-19 among household contacts	10	9	7	Hydroxychloroquine, azithromycin	Basiliximab, methylprednisolone	Tacrolimus, mycophenolate mofetil, prednisone	Alive
H	H	Heart	Dyspnea, fever, diarrhea	9	Suspected nosocomial transmission at transplant center	84	77	9	Remdesivir, azithromycin, tocilizumab	Basiliximab, methylprednisolone, mycophenolate mofetil	Tacrolimus, mycophenolate mofetil, methylprednisolone	Alive

*For all recipients, SARS-COV-2 test was by nasopharyngeal swab. COVID-19, coronavirus disease; HCW, healthcare worker; ICU, intensive care unit; SARS-COV-2, severe acute respiratory syndrome coronavirus 2.
†If patient never discharged since organ transplantation, number of days hospitalized since organ transplantation. If patient discharged and re-admitted, number of days hospitalized since most recent admission.
‡For patients C, D, and F, day of death is considered last day of hospitalization, day in ICU, or day intubated.